Equillium, Inc. (EQ)

Market Cap	61.88M
Revenue (ttm)	4.39M
Net Income (ttm)	-24.42M
Shares Out	59.50M
EPS (ttm)	-0.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,352,251
Open	0.840
Previous Close	0.840
Day's Range	0.756 - 1.060
52-Week Range	0.270 - 2.350
Beta	1.88
Analysts	Hold
Price Target	1.00 (-3.85%)
Earnings Date	Nov 13, 2025

About EQ

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ul...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 11, 2018
• Employees: 35
• Stock Exchange: NASDAQ
• Ticker Symbol: EQ
• Website: https://www.equilliumbio.com

Financial Performance

In 2024, Equillium's revenue was $41.10 million, an increase of 13.89% compared to the previous year's $36.08 million. Losses were -$8.07 million, -39.51% less than in 2023.

Analyst Summary

According to one analyst, the rating for EQ stock is "Hold" and the 12-month stock price target is $1.0.

Price Target

$1.0

(-3.85% downside)

Analyst Consensus: Hold